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ABSTRAK
Tujuan: menilai efektivitas stimulasi saraf tibia perkutaneus/percutaneous tibial nerve stimulation (PTNS) 
untuk OAB non-neurogenik pada orang dewasa secara sistematik dengan membandingkan prosedur semu (sham 
procedure) dan terapi lainnya. Metode: kami melakukan kajian sistematis atas penelitian kohort. Sumber data 
meliputi MEDLINE, EMBASE, CINAHL, National Library for Health, Cochrane dan google scholar dari tahun 2005 
hingga 2015. Meta analisis dilakukan dengan menggunakan model efek acak (random effects model). Heterogenitas 
efek tersebut dinilai dengan menghitung statistik I2. Analisis statistik dilakukan menggunakan program Review 
Manager 5.3 untuk meta analisis uji klinis acak (RCT meta-analysis). Hasil: kami menganalisis 11 uji klinis acak 
terkontrol atau randomised controlled trial (RCT) dan lima penelitian prospektif non-komparatif dengan tingkat 
keberhasilan yang beragam. Berdasarkan persentase responden, hasilnya adalah 37,3% - 81,8% untuk kelompok 
PTNS, 0% - 20,9% untuk kelompok sham, 54,8% untuk kelompok anti-muskarinik dan 89,7% untuk kelompok 
multimodal. Berkurangnya episode gejala berkemih per hari ditemukan pada kelompok PTNS (0,7-4,5), sham (0,3-
1,5) dan kelompok anti-muskarinik (0,6-2,9). Pada meta-analisis empat RCT, hasilnya menunjukkan bahwa PTNS 
lebih baik daripada prosedur sham dengan rasio risiko keseluruhan sebesar 7,32 (IK95% 1,69-32,16), p=0,09, 
I2=54%. Kesimpulan: terdapat bukti efektivitas PTNS jangka pendek sebagai terapi untuk OAB non-neurogenik. 
PTNS terbukti lebih baik secara bermakna dibandingkan prosedur sham.
Kata kunci: overactive bladder, percutaneous tibial nerve stimulation, sham, anti-muskarinik, gejala berkemih.
ABSTRACT
Aim: to evaluate the effectiveness of short-term PTNS for non-neurogenic OAB in adults systematically by 
comparing with sham procedure and other treatments. Methods: we performed a systematic review of cohort study. 
Data sources were MEDLINE, EMBASE, CINAHL, National Library for Health, Cochrane, and google scholar 
from 2005 through 2015. Meta-analysis was performed using the random effects model. Heterogeneity of effects 
was assessed by calculating I2 statistic. Statistical analysis was performed using Review Manager 5.3 for RCT 
meta-analysis. Results: we analized 11 randomised controlled trial (RCT) and five prospective non-comparative 
studies with variable success rate. Based on percentage of responders, the results were 37.3% - 81.8% in PTNS 
group, 0% - 20.9% in sham group, 54.8% in anti-muscarinic group, and 89.7% in multimodal group. The decrease 
of voiding symptoms episodes per day was found in PTNS (0.7-4.5), sham (0.3-1.5), and anti-muscarinic (0.6-2.9) 
groups. In meta-analysis of four RCTs, the results favour PTNS over sham procedure with overall risk ratio of 7.32 
(95% CI of 1.69-32.16), p=0.09, I2=54%. Conclusion: there is an evidence of effectiveness of short term PTNS 
in treatment of non-neurogenic OAB. PTNS is proven significantly better than sham procedure.
Key words: overactive bladder, percutaneous tibial nerve stimulation, sham, anti-muscarinic, voiding symptoms.
Vol 47 • Number 3 • July 2015                             Effectiveness of short term percutaneous tibial nerve stimulation
189
INTRODUCTION
Overactive bladder (OAB) is a common 
condition which refers to urgency with or without 
urgency incontinence, usually with frequency 
and nocturia in the absence of an underlying 
metabolic or pathological condition.1 This 
problem is pervasive and has considerable effects 
on the quality of life.  Around 455 million people 
(11% of the world population) are estimated to 
experience OAB symptoms during their life. 
The reported OAB prevalence in adult varies 
from 10.2% to 17.4% in males and 7.7 – 31.3% 
in females.1-3 Urinary incontinence affects one-
third of patients with OAB and thus associated 
with adverse effects on patients’ health-related 
quality of life (HRQoL) as well as social 
interactions, sleep, depression and sexual health. 
Despite the high prevalence and impact of OAB, 
almost 60% of people with OAB do not seek 
medical assistance because of embarrassment 
of misconception of the disease.4,5
First line treatments of OAB are conservative 
treatment including bladder training, pelvic floor 
muscle training, and anti-muscarinic medication. 
Unfortunately, despite its effectiveness, only 
approximately 20% of OAB patients persist 
on medication therapy after 6 months. It is due 
to the fact of most commonly adverse events 
reported, such as dry mouth and constipation.6,7 
Then, patients with those conditions have 
treatment options like invasive surgery such as 
bladder augmentation, detrusor myomectomy, 
and urinary diversion or less invasive methods 
of treatment like botulinum toxin injection to the 
bladder and neuromodulation.
Percutaneous Tibial Nerve Stimulation 
(PTNS) is defined as a minimally invasive 
n e u r o m o d u l a t i o n  s y s t e m  d e l i v e r i n g 
electrical stimulation to sacral nerve plexus 
through stimulation of posterior tibial nerve 
percutaneously. This nerve consists of mixed 
sensory motor nerve fibers originating from 
L4 through S3 which control modulation of 
innervation to the bladder, urinary sphincter, 
and pelvic floor. The system may have effect 
both on detrusor and micturition centers in the 
brain.8 The stimuli is delivered by using a fine, 
34-gauge needle electrode inserted just above 
the medial aspect of ankle. Commonly, PTNS 
cycles consist of 12-weekly treatment of 30 
minutes with nocturia and urge incontinence, 
after 4 to 6 treatment as evaluated parameters.9,10 
The use of PTNS for OAB resistant to first line 
therapy is recommended by National Institute 
for Health and Clinical Excellence (NICE), 
European Association of Urology (EAU). In fact, 
the studies supporting guidelines really vary in 
terms of method, comparison, population, and 
outcome measured. Moreover, the success rates 
of PTNS use in OAB treatment have a great 
variation as well.
Therefore, this systematic review is 
necessary to solve this problem. The purpose 
of this study is to evaluate PTNS treatment 
for OAB systematically. Specifically, we limit 
the studies to non-neurogenic OAB only. The 
effectiveness of PTNS will be compared with 
sham procedure as well as other treatment like 




All English language, prospective studies 
published on international journals in the last ten 
years were included in this review. Participants 
considered in the study were adults, with overactive 
bladder symptoms. Only studies describing effect 
of PTNS were included. Outcome measures were 
percentage of responders or patients with positive 
response and voiding diaries parameters including 
frequency, nocturia, urgency, incontinence, and 
voided volume.
Information Source
A literature search was performed using 
MEDLINE, EMBASE, CINAHL, National 
Library for Health, Cochrane and google scholar. 
The last literature search was run on January 
2015.
Search
Search terms used were based on PICO 
formula. Related articles of relevant papers were 
also searched thoroughly.
Study Selection
Studies with randomized clinical trials 
and prospective study design about PTNS in 
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non-neurogenic OAB based on PICO criteria 
were included. The exclusion criterias were 
non-English articles, case reports or case series, 
studies about PTNS non reporting clinical results 
and retrospective studies.
Data Extraction and Quality assessment
Quality of study was assessed by reviewing 
papers titles and abstracts. 
Statistical Analysis
Meta-analysis was performed using the 
random effects model. Heterogeneity was 
assessed by calculation the I2 statistic (low (25%-
50%), moderate (50%-75%) and high (>75%)). 
Statistical analysis was performed using Review 
Manager 5.3 for RCT meta-analysis.
RESULTS
Evidence Synthesis
We included 16 studies in total. Figure 1 
summarizes the flow for study selection for this 
systematic review. There were 11 randomised 
clinical trial (RCT) studies and five prospective 
non-comparative studies which described 
effectiveness of PTNS (Table 1). Other studies 
were excluded as they did not meet inclusion and 
exclusion criterias.
Methodological Quality
Table 2 shows the methodological quality of 
the RCT included in this systematic review using 
Jadad scale. There were 5/11 studies with good 
Table 1. PICO formula
Criteria Search terms
Patients (P) Adult patients with non-neurogenic OAB “overactive bladder” or “detrusor overactivity” or “urgency”
Intervention (I) Percutaneous tibial nerve stimulation (PTNS)
“neuromodulation” or “tibial nerve” or 
“percutaneous tibial nerve stimulation” or 
“posterior tibial nerve stimulation”
Comparison (C) Sham nerve stimulation, anti-muscarinic medication, combination therapy, no comparison
“sham” or “placebo” or “anti-muscarinic” 
or “combination therapy” or “multimodal 
therapy”
Outcomes (O)
percentage of responders or patients with positive 
response and voiding diaries parameters including 






Records identified in Embase,
CINAHL, National Library for Health
Records identified
in google scholar








Figure 1. Search strategy used for systematic review of PTNS in OAB
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Table 2. Characteristic of the studies
No Author, year Randomized Gender Treatment groups Age N Dosage Duration
1 Souto et al, 201411 RCT females PTNS 56.9 (33–77) 18 30 min; 2x/week 12 weeks
Oxybutinyn 57.7 (34–79) 19 10 mg; daily 12 weeks
PTNS + 
Oxybutynin 60.1 (33–77) 21
30 min; 2x/week (PTNS) 
and 10 mg; daily 
(Oxybutynin)
12 weeks
2 Vecchiolli et al, 201312
RCT 
(crossover) females PTNS 63 (41-81) 16 30 min; 2x/week 6 weeks
Solifenacin 61 (35-79) 14 5 mg; 1x/day 40 days
Succinate
3
Polo et al, 
201213 NRCT females PTNS 60.8 14
8 weekly sessions, 4 
sessions every 15 days, 2 
monthly session
4 Agro et al, 201014 RCT females PTNS 44.9 17 30 min; 3x/week 4 weeks





RCT Mixed PTNS 62.5 103 30 min; 1x/week 12 weeks
Sham 60.5 105 30 min; 1x/week 12 weeks
6 Yoong et al, 201016 NRCT females PTNS 55.3 (21-91) 43 30 min; 1x/week 6 weeks
7 Sancaktar et al, 201017 RCT females Tolterodine 45.4-8.7 18 4 mg; 1x/day 12 weeks
Tolterodine 
+ PTNS 47.4-10.1 20
4 mg; 1x/day (Tolterodine) 





RCT mixed PTNS 57.5-15.2 44 30 min; 1x/week 12 weeks
Tolterodine 58.2-11.3 42 4 mg; 1x/day 12 weeks
9 Agro et al, 200919 RCT females PTNS 47-10.5 16 30 min; 3x/week 4 weeks
sham 42-7 8 30 min; 3x/week 4 weeks
10 Preyer, 2007 (abstract)20 RCT females PTNS 16 30 min; 1x/week 12 weeks
Tolterodine 59.4-10.9 15 2 mg; 2x/day 12 weeks
11 Van Balken et al, 200621 NRCT mixed PTNS 54.1 (21-82) 83 30 min; 1x/week 12 weeks
12 Nuhoglu et al, 200622 NRCT females PTNS 47.3±8.4 35 30 min; 1x/week 10 weeks
13 Van Der Pal et al, 200623 NRCT mixed PTNS 51 (33-66) 11 30 min; 3x/weeks 4 week
14 Agro et al, 200524 RCT mixed PTNS 17 30 min; 1x/week 12 weeks





RCT females PTNS 43.5 8 30 min; 1x/week 12 weeks
Sham 45.8 8 30 min; 1x/week 12 weeks
16 Karademir et al, 200526 RCT mixed PTNS 40.3 21 60 min; 1x/week 8 weeks
PTNS + 
Oxybutynin 43.1 22 5 mg; 1x/day 8 weeks
RCT=randomized controlled trial, NRCT = non randomized controlled trial
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or excellent quality (Jadad score of 3 or more). 
Specifically, among 4 studies comparing PTNS 
with sham procedure, 3 studies had good quality.
Participants and Intervention
PTNS studies comprised a total of 787 adult 
participants, in which 480 patients treated with 
PTNS, 108 patients treated with anti-muscarinic, 
63 patients treated with combination therapy, 
and 136 patients treated with sham treatment 
or placebo. In all studies the number of female 
patients was higher than male patients. Ten 
out of 16 studies were only on females. In the 
studies included, age ranges between 21 and 91 
years old.
Comparison
Among 11 RCT included, there were four 
studies comparing PTNS with sham therapy, 
three compared PTNS with anti-muscarinic 
therapy, two compared PTNS with combination 
therapy (PTNS and anti-muscarinic), one 
compared anti-muscarinic with combination 
therapy, and one compared PTNS once a week 
with three times a week. In addition, there were 
five prospective studies with no comparative 
group.
Outcome
In Table 3, studies have reported variable 
success rates for treating OAB symptoms 
with PTNS (37.3% - 81.8%), sham procedure 
(0% - 20.9%), anti-muscarinic (54.8%), and 
multimodal therapy with PTNS and anti-
muscarinic (89.7%). Success rate for each study 
varied depending on the criteria determined 
by each author. For example, there were some 
studies using criterias such as improvement 
on Global Response Assessment (GRA)13-15,17, 
50% or greater reduction in symptoms (urgency, 
frequency, incontinence episodes)14,16-19,20-26, and 
subjective feelings of improvement.13,21 Table 4 
shows objective parameters of studies included in 
this systematic review including voiding diaries 
parameters such as frequency, nocturia, urinary 
incontinence and urgency episodes, as well as 
voided volume.
PTNS vs Sham Procedure
When compared to sham procedures, the 
number or percentage of responders in PTNS 
group were statistically higher (p<0.01), not 
only in objective responses14,19,25 but also in 
GRA improvement or cure.15 Study by Agro et 
al14 showed significant reduction of frequency 
episodes per day and urinary incontinence 
episodes per 3 days  in PTNS group, but not 
in sham group. Two other studies by Peters et 
al15 and Agro et al25 showed significantly higher 
reduction of frequency and nocturia episodes per 
day in PTNS group compared to sham group. 
In the matter of voided volume, two studies 
comparing PTNS and sham procedure showed 
significant increase of voided volume (p<0.001) 
Table 3. Methodological quality of studies
Study Treatment Randomization Blinding Withdrawal Score
Souto et al, 201411 PTNS vs anti-muscarinic vs combination 2 0 0 2
Vecchiolli et al, 201312 PTNS vs anti-muscarinic 1 0 1 2
Agro et al, 201014 PTNS vs sham 2 1 0 3
Peters et al, 201015 PTNS vs sham 2 1 1 4
Sancaktar et al, 201017 Anti-muscarinic vs combination 2 0 1 3
Peters et al, 200918 PTNS vs anti-muscarinic 2 0 1 3
Agro et al, 200919 PTNS vs sham 1 1 1 3
Preyer, 2007 (abstract)20 PTNS vs anti-muscarinic 1 0 1 2
Agro et al, 200524 PTNS (1x/week) vs PTNS  
(3x/week)
1 0 0 1
Agro et al, 2005 
(abstract)25
PTNS vs sham 1 0 0 1
Karademir et al, 200526 PTNS vs combination 1 0 0 1
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Table 4. Responders of PTNS studies
Author, year Definition of responders
Number of responders (percentage)
p
PTNS Sham Anti-muscharinic Combination
Polo et al, 201213 Subjective improvement of 
symptoms 50% - - - -
Agro et al, 201014 50% or greater reduction in 
incontinence episodes
moderately or markedly 
improved on a 7-level global 
response assessment 
(GRA) 
12/17 (71%) 0/15 (0%) - - P<0.001




(20.9%) - - <0.001
Yoong et al, 
201016
OAB symptoms no 
longer being bothersome, 
reduction by 50% in 
frequency episodes, 




30/43 (69.7%) - - - -
Peters et al, 
200918
GRA improvement or cure 35/44 (79.5%) - 23/42 (54.8%) - P=0.01
Agro et al, 200919 Reduction >50% of urgency 
episodes 10/16 (62.5%) 0/8 (0%) - - -
Van Balken et al, 
200621
>50% reduction in 





- - - -
Nuhoglu et al, 
200622
Complete recovery after 
treatment (<8 voids/24h, 0-1 
urgency episodesday, no 
urinary incontinence
19/35 (54.2%) - - - -
Van Der Pal et al, 
200623
>50% fewer incontinence 
episodes and/or void 9/11 (81.8%) - - - -
Agro et al, 200524 Reduction >50% of the 
micturition episodes/24h 






- - - -
Agro et al, 2005 
(abstract)25
50% reduction in urinary 
incontinence episodes 6/8(75%) 0/8 (0%) - - -
Karademir et al, 
200526
Overall treatment response 
rate 61.6% - - 83.2% P<0.0001
in PTNS group but not significant in sham 
group.14,15 Figure 2 shows the meta-analysis of 
four RCTs comparing PTNS to sham procedure. 
Number of responders, patients with successful 
treatment, was considered as “event” (outcome) 
and expressed in risk ratio with 95% confidence 
of interval. The results demonstrate that all of the 
studies favour PTNS over sham procedure with 
overall risk ratio of 7.32 (95% CI of 1.69-32.16). 
It means that patients in PTNS group were seven 
times more likely to be successful in treatment 
compared to sham procedure. Heterogeneity 
among studies was not significant as stated in 
p value (0.09) and I2 (54%). In addition, the 
number needed to treat (NNT) calculated was 
4.28 (95% CI of 3.19-6.49).
PTNS vs Anti-muscarinic Therapy
In studies comparing PTNS and anti-
muscarinic, there were variable results in 
changes of voiding diaries symptoms. Most of 
them showed significant reduction of symptoms 
in both groups with no significant difference. 
In studies comparing PTNS and multimodal 
therapy, there was one study by Sancaktar et al17 
showing the significant difference of symptoms 
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Table 5. Voiding diaries of PTNS studies











1 Frequency/  
24h
Souto et al, 
201411






PTNS 11.4+1.4 9.4+1.9 0.0006
Solifenacin 11.6+1.2 10.0+2.1 0.0039
Polo et al, 
201213
PTNS 12.64+6.8 10.21+6.13 0.05










Peters et al, 
201015
PTNS 12.3+3.2 9.8+2.8 -2.4+2.5 <0.001 -0.9+2.5
Sham 12.4+3.0 11.0+3.1 -1.5+2.4 <0.001 P=0.01











Tolterodine 12.8+1.3 6.4+0.6 <0.001 >0.05 (before)
Tolterodine + 
PTNS 12.2+1.2 4.5+0 <0.001
<0.05 
(after)
Peters et al, 
200918
PTNS 12.1+3.1 9.8+3.0 -2.4+4.0 <0.001 0.44




3.6) 0.1 (-3.3-3.6) 0.77
Tolterodine 0.7 (-2.3-
3.7) 0.7 (-2.3-3.7) 0.77
Nuhoglu et 
al, 200622
PTNS 11.2+2.9 7.4+1.5 <0.01
Van Der Pal 
et al, 200623
PTNS 12.0 (6.5) 9.2 (2.9)
Agro et al, 
200524
PTNS (1x/week) 3 (1-5) 1 (0-3) 0.01









PTNS 11.7 7.4 36.7% 0.48
PTNS + 
Oxybutynin 11.3 6.3 44.2%
2 Nocturia 
/24h
Souto et al, 
201411
PTNS 94% 11% <0.0001 P=0.24
Oxybutynin 84% 5% <0.0001
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PTNS + 
Oxybutynin 95% 14% <0.0001
Vecchiolli et 
al, 201312
PTNS 2.6+1.4 1.7+0.9  0.0419
Solifenacin 2.7+1 1.9+1.4 0.0312
Polo et al, 
201213
PTNS 3.14+2.14 2.71+2.2 0.472
Peters et al, 
201015
PTNS 2.9+1.6 2.1+1.4 -0.7+1.2 <0.001 -0.4+1.3
Sham 2.9+1.7 2.6+1.6 -0.3+1.4 0.02 p=0.04








Peters et al, 
200918
PTNS 2.5+1.2 1.7+1.1 -0.7+1.0 <0.001
Tolterodine 2.5+1.4 1.9+1.6 -0.6+1.7 0.03
Van Der Pal 
et al, 200623




Souto et al, 
201411
PTNS 94% 
patients 11% patients <0.0001 P=0.33
Oxybutynin 100% 
patients 31% patients <0.0001
PTNS + 





Van Der Pal 
et al, 200623
PTNS 7.4 (12.0) 3.1 (4.) <0.05
Agro et al, 
200524
PTNS (1x/week) 12 (8-22) 8 (5-15) 0.01










Agro et al, 
201014
PTNS
4.1 (3.3-5.2) 1.8 (1.2-2.2) <0.001





























Peters et al, 
200918
PTNS 2.2+2.3 1.2+1.6 -1.0+2.2 0.007
Tolterodine 3.5+3.5 1.8+2.5 -1.7+3.8 0.006
Nuhoglu et 
al, 200622
PTNS 2.3+1 0.8+0.7 <0.01




PTNS 3.7 3.9 70.2%
PTNS + 





PTNS 3.44+1.41 1.7+1.5 0.0002
Solifenacin 3.7+0.9 2.6+1.6 0.0078 
Polo et al, 
201213










PTNS 12.4+0.9 5.7+0.6 <0.001
Peters et al, 
200918
PTNS 6.0+4.1 3.9+2.8 -2.2+4.3 0.002







PTNS 3.5+1.8 1.9+1.3 <0.01
Karademir et 
al, 200526
PTNS 6.3 3.4 46.1% 0.43
PTNS + 





PTNS 114.9+14.5 156.1+18.4 <0.0001
Solifenacin 121.6+26.4 147.4+27.5 0.0215












Peters et al, 
201015
PTNS 169.5+78.9 183.0+75.6 11.4+45.0 0.01 5.5+42.1
Sham 168.7+84.0 172.6+90.6 5.9+39.0 0.13 p=0.35
Peters et al, 
200918
PTNS 152.7-79.3 185.5-81.1 32.8+61.3 0.001
Tolterodine 141.2+76.2 158.7+99.8 17.6+58.4 0.06
Nuhoglu et 
al, 200622
PTNS 148.3+49.1 178+53.2 <0.01
Van Der Pal 
et al, 200623
PTNS
107.6 (51.5) 187.5 (100.6) <0.05
episodes between PTNS and multimodal 
therapy (PTNS and anti-muscarinic) favouring 
multimodal therapy. Karademir et al26 also found 
significantly higher response rate of multimodal 
therapy group compared to PTNS only group. 
Among several studies comparing PTNS and 
anti-muscarinic, there was one study measuring 
significant reduction in percentage of patients 
having nocturia and urinary incontinence in 
both treatment (p<0.0001) with no significant 
difference between two groups.11 In addition, in 
one study 35/44 (79.5%) patients in PTNS group 
reported a subjective improvement compared 
to 23/42 (54.8%) in anti-muscarinic group 
(p=0.01)18. Another study showed patients in 
both groups have significant increase of voided 
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volume (p<0.05) with higher changes in PTNS 
group.12 Peters et al18 also found that increase of 
voided volume was significant in PTNS group 
(p=0.001) and insignificant in anti-muscarinic 
group (p=0.06).
PTNS in Noncomparative Studies
In noncomparative studies, patients with 
PTNS treatment had significant reduction in 
frequency episodes per day 13,16,22,23, as 
well as in urinary incontinence episodes23 
and urgency episodes.13,22 Among 3 studies 
evaluating nocturia, there was one study showing 
insignificant reduction in nocturia episodes per 
day13, while the two others showed significant 
reduction of this symptom.16,23 In a study by Agro 
et al24 comparing frequency of PTNS treatment, 
there was no significant difference between them. 
The number of responders were 11/17 (63%) and 
12/18 (67%) in once a week treatment and three 
times a week treatment, respectively.
DISCUSSION
Recently, there have been some systematic 
reviews published on the effectiveness of PTNS 
in adult patients with OAB.27-31 However, more 
recent studies have not yet been included in those 
reviews. Therefore, it is necessary to analyze 
more data as the knowledge of PTNS in OAB 
is still evolving.
The studies included in this systematic 
review demonstrated variable success rate for 
treating OAB with PTNS, sham procedure, 
anti-muscarinic, and multimodal therapy (PTNS 
and anti-muscarinic). Based on percentage of 
responders, the results were 37.3% - 81.8% 
in PTNS group21,23 and 0% - 20.9% in sham 
group.14,19,25 Peters et al18 showed that GRA 
improvement in those treated with anti-muscarinic 
therapy was 54.8%. Moreover, Karademir et al26 
showed high rate of overall treatment response 
in patients treated with combination therapy 
(89.7%). The decrease of voiding problems 
episodes per day was found in PTNS (0.7-4.5), 
sham (0.3-1.5) and anti-muscarinic (0.6-2.9) 
groups.15,18,25
Effectiveness of PTNS in OAB, specifically 
in non-neurogenic OAB, has been proven 
in sham controlled trials both in number of 
positive responders and also in voiding diaries 
parameters of the patients. It is supported in this 
systematic review that patients who received 
PTNS treatment were seven times more likely 
to have successful treatment compared to sham 
treatment. The number of patients needed to 
treat to get one additional successful outcome 
was 4 people.
When compared to anti-muscarinic treatment, 
there were no significant differences in reduction 
of symptoms and increase of voided volume. 
However, in one study, patients in PTNS group 
had significantly higher GRA improvement 
compared to anti-muscarinic group.18 The 
possible explanation is that most of the studies 
included in this systematic review investigated 
patients who were already resistant to first line 
therapy of OAB, such as anti-muscarinic. On the 
other hand, multimodal therapy combining PTNS 
and anti-muscarinic therapy still had superior 
outcome compared to PTNS only.17,26 Besides 
sham controlled and anti-muscarinic controlled 
trial, we also included non-comparative studies. 
From those studies, patients treated with PTNS 
had significant reduction in frequency episodes 
as well as high response rate.13,16,21-24,26
Figure 2. Meta-analysis of randomized control trials PTNS versus Sham procedure
Elita Wibisono                                                                                                          Acta Med Indones-Indones J Intern Med
198
There were variable definitions of success 
among studies included in this systematic review. 
It might contribute to the wide results range 
obtained. The other things contributing to bias are 
variable gender of patients, dosage or frequency 
of PTNS and anti-muscarinic treatment, and tools 
used in voiding diaries outcome. For example 
there were episodes counted per day, per three 
days, and per week. Conclusively, there was no 
standardized protocol of PTNS treatment used 
in those studies. Therefore, to get better results, 
the future agenda is to reproduce RCT with one 
standardized protocol and more homogeneous 
patients. Since OAB is multifactorial, prognostic 
factor of successful response rate such as gender 
and age should be evaluated in the future. As an 
early finding, responder rate was found higher 
in females (66%) than in male patients (45%) 
receiving PTNS treatment.32
Studies included in this systematic review 
were RCTs and prospective non-comparative 
studies. Although non-comparative studies 
have lower level of evidence, they are the best 
available evidence to expand the information 
needed. Abstracts of scientific meeting were 
also included with exclusion of non-English 
language.
The effectiveness of short term PTNS 
therapy for OAB has been proven from the 
studies included. On the other hand, there is 
still lack of information on long term therapy 
of PTNS in OAB as it is needed to prevent 
deterioration of symptoms. Macdiarmid et al33 
evaluated the long term durability of PTNS in 
OAB by continuation of the second phase of 
The Overactive Bladder Innovative Therapy 
Trial (OrBIT) in which 33 responders of PTNS 
group received an additional 9 month of PTNS 
treatment. There were statistically significant 
OAB symptoms improvement achieved with 12 
weekly PTNS that demonstrated good durability 
through 12 months. This conclusion was 
obtained from 12 months mean improvements 
from baseline in frequency, urge incontinence, 
nocturia, and voided volume.33 Furthermore, 
there was Sustained Therapeutic Effects of PTNS 
(STEP) study which was the continuation from 
SuMIT study evaluating long term efficacy of 
PTNS. After successful 12 weekly treatments, 
patients continued with 14-week tapering 
protocol and personalized treatment plan. 
Improvements in frequency, urge incontinence, 
nocturia, and urgency episodes were statistically 
significant compared to baseline at 6, 12, 18, and 
24 months.34 At 3 years, they found 77% (95% 
CI, 64%-90%) of subjects with maintained or 
marked OAB improvements.35 All in all, PTNS is 
durable and can be a long term treatment option 
for OAB.
From the studies reported, PTNS had no 
serious adverse event. The rare events found in 
PTNS treatment were ankle bruising, discomfort/
pain at needle site, bleeding at needle site, 
tingling in leg, generalized swelling, worsening 
incontinence, headache, hematuria, inability 
to tolerate stimulation, intermittent foot/toe 
pain, and foot cramp.15,18,23 They were found in 
a few number of patients and considered rare. 
In long term PTNS therapy (STEP study), the 
events reported were urinary tract infection 
(UTI), pulling feeling on feet, bladder pressure, 
pinched nerve, and slow stream, with no direct 
relationship to PTNS.34 In patients receiving 
anti-muscarinic, the common adverse events 
were constipation, infection, dizziness, visual 
disturbance, and fatigue.18
In  a  s tudy  compar ing  PTNS and 
antimuscarinic, both treatments were well 
tolerated with no serious adverse events reported. 
It was stated that after 12 weeks of therapy, 
several symptoms were reported significantly 
less in the PTNS group compared to the 
antimuscarinic group, including dry mouth and 
constipation.18 Peter et al15 showed that there 
was no serious adverse events reported in PTNS 
group and sham group. 
Although the studies included in this 
review provided evidence favouring PTNS, 
this systematic review has several limitations. 
First, the dosage, duration, frequency, cycle, 
and follow-up durations of PTNS varied among 
studies. The variations were also found in study 
design and baseline data (age, gender). Therefore, 
further large scale, RCT with consistent study 
design, criteria, and clinical outcome evaluation 
are strongly needed to attain the long-term 
effectiveness of the PTNS.
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CONCLUSION
There is evidence of effectiveness of short 
term PTNS in treatment of OAB symptoms, 
especially non-neurogenic OAB. PTNS is 
proven significantly better than sham procedure 
and comparable to anti-muscarinic but with 
fewer systemic adverse events. On the other 
hand, multimodal therapy still gives higher 
effectiveness than PTNS alone. There is also an 
evidence of long term PTNS in OAB treatment 
indicating that PTNS may be an option for OAB 
maintenance treatment due to its durability and 
safety. Further studies are needed to evaluate this 
long-term effectiveness of PTNS in OAB and 
to find prognostic factor of successful response. 
Standardized protocol of PTNS prescription is 
needed to obtain homogeneous data, better result 
and analysis.
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